NEWS IN BRIEF
Innova Biosciences boosts Lightning-Link antibody labelling tech
![GettyImages/prudkov](/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_large/publications/pharmaceutical-science/biopharma-reporter.com/headlines/bio-developments/innova-biosciences-boosts-lightning-link-antibody-labelling-tech/7747878-1-eng-GB/Innova-Biosciences-boosts-Lightning-Link-antibody-labelling-tech.jpg)
The Lightning-Link platform – marketed by Innova Biosciences – is now available in volumes from 10µg to 100mg in single reaction vials.
“For antibody manufacturers that have fixed internal processes for conjugation, bulk supply of ultra-high quality raw materials and labels that are used in the Lightning-Link kits are also available,” said the firm.
The platform can be used in research & development (R&D) and drug discovery, and according to Innova Biosciences is the most efficient method of labelling antibodies or proteins on the market – with only 30 seconds hands-on time.
CEO Alastair Carrington said the extended capabilities will benefit both small and large-scale antibody manufacturers.
“Access to Lightning-Link technology will enable manufacturers to dramatically increase their conjugate portfolios, whilst retaining batch-to-batch consistency,” he added.
Last month, US Biological announced an antibody labelling deal with Innova Biosciences’ Lightning-Link technology.